Aquestive Therapeutics, Anaphylm, Dibutepinephrine, AQST-109, FDA, NDA Resubmission, PDUFA, March 2027, Anaphylaxis, Severe Allergic Reactions, Epinephrine

WARREN, N.J., October 15, 2026 Aquestive Therapeutics, Inc. (NASDAQ: AQST) announced that the U.S. Food and Drug Administration (FDA)...